OKYO Pharma Limited Sponsored ADR (OKYO) AI Stock Analysis

• Market Cap: $38.63M
• Dividend Yield: N/A
• Average Volume (3M): 151.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 76
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 33,886,314
• 10 Day Avg. Volume: 78,984
• 30 Day Avg. Volume: 151,733
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 514.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

OKYO Pharma Limited's overall stock score is low due to significant financial challenges, including lack of revenue, negative equity, and cash burn. While technical indicators show positive momentum, potential overbought conditions and the absence of valuation metrics add uncertainty. The company's financial instability and speculative nature in the biotechnology sector are significant concerns.

Positive Factors

Clinical Trials

OK-101 has demonstrated favorable safety and tolerability in a Phase 2 trial in dry eye disease, with statistically significant improvements in symptoms such as stinging/burning and ocular pain.

Market Potential

NCP represents an urgent unmet medical need and an effective NCP treatment may have significant market prospects.

Regulatory Milestones

OK-101 is the first NCP drug candidate that has received FDA IND clearance for clinical evaluation.

Negative Factors

Commercial Risks

Risks include failure to achieve commercial success due to market size, penetration rate, and/or competition.

Financial Risks

The company needs to raise additional capital within the next 12 months to fund operations.

Regulatory Risks

Risks include failure of OK-101 to secure regulatory approval in the U.S.

OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model

Company Description

OKYO Pharma Limited Sponsored ADR (OKYO) is a biotechnology company focused on the discovery and development of innovative therapeutics for inflammatory diseases and pain management. Operating primarily in the biopharmaceutical sector, the company is committed to leveraging its expertise in drug development to address unmet medical needs, particularly in the fields of ophthalmology and chronic pain.

How the Company Makes Money

OKYO Pharma Limited generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on licensing agreements, partnerships, and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on product sales. Additionally, OKYO may engage in research and development collaborations, receiving funding and resources to advance its drug candidates. Other potential revenue streams include government grants and research funding to support the company's innovative pipeline. However, as a company in the development stage, its earnings are significantly influenced by its ability to successfully bring its drug candidates to market and establish beneficial partnerships.

OKYO Pharma Limited Sponsored ADR Financial Statement Overview

Summary

OKYO Pharma Limited faces significant financial challenges, with no revenue generation, negative equity, and persistent cash outflows. These factors highlight substantial financial risk, especially given ongoing R&D investments without profitability improvements.

Income Statement

OKYO Pharma Limited has shown no total revenue over the past years, reflecting the challenges in generating sales typical in the biotechnology industry. Net income remains negative, indicating ongoing operational and developmental expenses without offsetting revenue.

Balance Sheet

The balance sheet indicates a concerning negative stockholders' equity, which is a risk factor for financial stability. The total liabilities exceed total assets, which may affect the company's ability to raise capital. The debt-to-equity ratio cannot be calculated due to negative equity, further highlighting financial risk.

Cash Flow

OKYO's cash flow is characterized by negative operating cash flow and free cash flow, suggesting significant cash burn typical for R&D-focused biotech firms. However, the company has managed to secure financing inflows, which partially mitigates cash flow concerns.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
―	―	―	―	-13.09K	―
	EBIT
―	―	-13.19M	-6.22M	―	-1.52M
	EBITDA
―	―	-13.18M	-6.22M	-3.35M	-1.51M
	Net Income Common Stockholders
―	―	-13.27M	-5.43M	-3.35M	-1.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.34M	826.85K	4.05M	2.70M	6.89M	234.96K
	Total Assets
45.20M	1.54M	5.20M	4.30M	7.09M	597.40K
	Total Debt
0.00	0.00	2.22M	0.00	98.76K	31.62K
	Net Debt
-14.34M	-826.85K	-1.83M	-2.70M	-6.79M	-203.34K
	Total Liabilities
183.32K	7.42M	7.26M	1.35M	1.77M	737.20K
	Stockholders Equity
45.02M	-5.88M	-2.05M	2.95M	5.32M	―
Cash Flow		Free Cash Flow
―	-9.49M	-7.70M	-5.47M	-1.61M	-1.20M
	Operating Cash Flow
―	-9.49M	-7.70M	-5.47M	-1.60M	-1.20M
	Investing Cash Flow
0.00	0.00	-5.92K	-1.67K	-18.11K	-132.67K
	Financing Cash Flow
―	6.21M	9.32M	2.15M	7.83M	963.31K

OKYO Pharma Limited Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.23, and below the 200-day MA of 1.14, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 41.88 is Neutral, neither overbought nor oversold. The STOCH value of 15.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OKYO.

OKYO Pharma Limited Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ECOR	54 Neutral	$40.71M	―	-158.63%	―	57.09%	52.18%
BNR	52 Neutral	$37.59M	―	-51.22%	―	-10.56%	41.02%
Sector *	48 Neutral	$6.36B	1.09	-49.92%	2.63%	17.17%	0.95%
RPTX	46 Neutral	$42.51M	―	-46.63%	―	4.58%	10.59%
OKYO	42 Neutral	$38.63M	―	0.00%	―	―	―
HOWL	36 Underperform	$31.30M	―	-76.33%	―	-90.55%	-55.06%